Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/PhysRevLett.89.279601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment: Ensuring Patient-Centered Care With Screening Contrast-Enhanced Mammography-A Call to Action.
AJR Am J Roentgenol
January 2025
Banner MD Anderson Cancer Center, Division of Diagnostic Imaging, 2946 East Banner Gateway Drive, Gilbert, Arizona 85234.
Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.
World J Gastroenterol
January 2025
Department of Radiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.
In this article, we comment on the article by Cheng published in recently. Posthepatectomy liver failure (PHLF) remains a leading cause of hepatectomy-related mortality and can be evaluated according to liver reserve function. Liver stiffness (LS) measured by ultrasonic elastography and spleen area demonstrate a strong correlation with hepatic proliferation, fibrosis, and portal vein congestion, thus indirectly reflecting liver reserve function.
View Article and Find Full Text PDFFlurpiridaz F 18: First Approval.
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFReply to Troisi et al. Comment on "Cabrera-Aguas, M.; Watson, S.L. Updates in Diagnostic Imaging for Infectious Keratitis: A Review. 2023, , 3358".
Diagnostics (Basel)
January 2025
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2000, Australia.
We appreciate the interest of Troisi and his colleagues [...
View Article and Find Full Text PDFComment on Cabrera-Aguas, M.; Watson, S.L. Updates in Diagnostic Imaging for Infectious Keratitis: A Review. 2023, , 3358.
Diagnostics (Basel)
January 2025
Ophthalmologic Unit, Salerno Hospital University, 84100 Salerno, Italy.
We read with great interest the recent article by Cabrera-Aguas M [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!